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Abstract 
Inappropriate activation of mammalian/mechanistic target of rapamycin complex 1 
(mTORC1) is common in cancer and has many cellular consequences including elevated 
endoplasmic reticulum (ER) stress. Cells employ autophagy as a critical compensatory 
survival mechanism during ER stress. This study utilised drug-induced ER stress through 
nelfinavir in order to examine ER stress tolerance in cell lines with hyper-active mTORC1 
signalling. Our initial findings in wild type cells showed nelfinavir inhibited mTORC1 
signalling and upregulated autophagy, as determined by decreased rpS6 and S6K1 
phosphorylation, and SQTSM1 protein expression, respectively. Contrastingly, cells with 
hyper-active mTORC1 displayed basally elevated levels of ER stress which was greatly 
exaggerated following nelfinavir treatment, seen through increased CHOP mRNA and XBP1 
splicing. To further enhance the effects of nelfinavir, we introduced chloroquine as an 
autophagy inhibitor. Combination of nelfinavir and chloroquine significantly increased ER 
stress and caused selective cell death in multiple cell line models with hyper-active mTORC1, 
whilst control cells with normalised mTORC1 signalling tolerated treatment. By comparing 
chloroquine to other autophagy inhibitors, we uncovered that selective toxicity invoked by 
chloroquine was independent of autophagy inhibition yet entrapment of chloroquine to 
acidified lysosomal/endosomal compartments was necessary for cytotoxicity. Our research 
demonstrates that combination of nelfinavir and chloroquine has therapeutic potential for 
treatment of mTORC1-driven tumours.  
  
 
 
  
  
1. Introduction 
The mammalian/mechanistic target of rapamycin complex 1 (mTORC1) pathway is 
frequently hyper-activated in cancer. mTORC1 regulates many processes linked to cancer, 
such as cell growth, proliferation, metastasis, autophagy, metabolism and angiogenesis. 
mTORC1 hyper-activation through genetic mutations of upstream components also 
underlies several tumour predisposition syndromes, such as tuberous sclerosis complex 
(TSC) and Cowden disease/PTEN hamartoma syndrome (Krymskaya and Goncharova, 2009). 
TSC is an autosomal dominant condition caused through mutations in either TSC1 or TSC2 
and is characterised by tumour growth in multiple organs, neurocognitive problems and 
epilepsy (for review see Kohrman, 2012). The TSC1 and TSC2 tumour suppressor proteins 
together with TBC1D7 form a functional complex which has GTPase-activating protein 
activity towards Ras homologue enriched in brain (Rheb). Rheb-GTP potently activates 
mTORC1, while conversion of Rheb-GTP to an inactive GDP-bound state by 
TSC1/TSC2/TBC1D7 turns off mTORC1 (Tee et al., 2003, Dibble et al., 2012). Consequently, 
loss-of-function mutations in either TSC1 or TSC2 cause aberrant signal transduction 
through mTORC1. Mutations of TSC1, TSC2 and mTOR occur in some sporadic cancers, but 
more common components within mitogenic signalling upstream of mTORC1 are altered, 
such as PTEN or RAS within PI3K and MAPK pathways, respectively. TSC1 is mutated in 
approximately 15% of bladder cancers and 3% of clear cell renal carcinomas; TSC2 is 
mutated in 3% of bladder cancers and in 8% of well-differentiated pancreatic 
neuroendocrine tumours and activating mTOR kinase domain mutations have been 
identified in intestinal adenocarcinomas and clear cell renal carcinomas (Platt et al., 2009, 
Sjodahl et al., 2011, Jiao et al., 2011). Frequent mutations affecting the wider PI3K/PTEN-
Akt-mTOR signalling network have also been reported in clear cell renal cancers and head 
and neck cancer (Sato et al., 2013, Liao et al., 2011).  
Aberrant signalling through mTORC1 is known to enhance the basal levels of ER stress, 
which is done in part by heightened levels of de novo protein synthesis, leading to an 
accumulation of unfolded proteins within the ER (Kang et al., 2011, Ozcan et al., 2008). 
mTORC1 further enhances the burden of ER stress through autophagy repression, as 
autophagy is utilised by the cell to remove unfolded protein aggregates to restore the 
protein folding environment within the ER (Høyer-Hansen and Jäättelä, 2007). Related work 
highlighting the crosstalk between autophagy and ER homeostasis showed that induction of 
ER stress by thapsigargin was via impairment of autophagosome-lysosome fusion (Ganley et 
al., 2011). Elevated cell stress is common in cancer and could potentially be exploited 
therapeutically (Hanahan and Weinberg, 2011). For instance, it is recognised that 
compromised stress recovery pathways in cancer cells may confer sensitivity to stress-
inducing drugs as many cancer cell lines are sensitive to endoplasmic reticulum (ER) stress-
inducers (Liu et al., 2012, Li et al., 2013, Zang et al., 2009), where excessive or prolonged ER 
stress leads to cell death (for review see Appenzeller-Herzog and Hall, 2012).  
 The mTOR inhibitor and rapamycin analogue, everolimus, is licensed for the treatment of 
renal angiomyolipomas and subependymal giant cell astrocytomas in patients with TSC (for 
review see Kohrman, 2012). However, rapalogues only induce partial regression of tumour 
volume and the tumours often regrow following treatment cessation (Franz and Weiss, 
2012). Evidently, alternative therapeutic strategies must be explored for mTORC1-driven 
tumours and targeting existing stress pathways is one possibility. Ozcan et al., (2008) and Di 
Nardo et al., (2009) demonstrated that Tsc2-/- cells elicited a higher level of ER stress that 
was dependent on aberrant signalling through mTORC1. In addition, tumours derived from 
TSC patients were also observed to have increased levels of ER stress. Supporting the notion 
that targeting this already elevated ER stress pathway in Tsc2-/- cells is a therapeutic option, 
both cellular and murine models of TSC have proved to be sensitive to ER stress-inducers 
such as thapsigargin (Siroky et al., 2012, Kang et al., 2011, Ozcan et al., 2008). ER stress 
upregulates autophagy as part of the unfolded protein response; a cytoprotective process 
purposed to alleviate ER stress through removal of misfolded protein products (He and 
Klionsky, 2009). Cells lacking Tsc2 show an attenuated autophagic response due to mTORC1-
mediated repression despite elevated levels of ER stress (Siroky et al., 2012, Parkhitko et al., 
2011).  
In this study we utilised nelfinavir, an ER stress-inducer that was originally clinically 
approved for treatment of human immunodeficiency virus infection. Nelfinavir was more 
recently observed to have anti-cancer activity in pre-clinical cell and xenograft models and is 
currently being investigated in multiple clinical trials (Buijsen et al., 2013, Pan et al., 2012, 
Rengan et al., 2012, Alonso-Basanta et al., 2014). Nelfinavir has been shown to affect many 
cellular processes linked to ER homeostasis including proteasome inhibition, impairment of 
signal transduction through the PI3K/Akt pathway and induction of autophagy, although 
some actions appear cell type dependent (Gills et al., 2007). We also employed chloroquine, 
a widely-used anti-malarial drug which has multiple effects on cells including alteration of 
mitochondrial and lysosomal membrane potential and arrest of autophagy flux in the later 
stages through alteration of lysosomal pH (Poole and Ohkuma, 1981). There is current 
interest in the clinical use of chloroquine in combination with conventional and novel anti-
cancer agents (Goldberg et al., 2012, Solomon and Lee, 2009, Sotelo et al., 2006). The 
rational for the use of chloroquine in these combinations is often inhibition of a presumed 
protective autophagic response. However, there is emerging evidence in some contexts that 
the cytotoxic action of chloroquine may be largely independent of autophagy inhibition 
(Maycotte et al., 2012, Harhaji-Trajkovic et al., 2012, Seitz et al., 2013). Herein, we 
examined the effects of nelfinavir and chloroquine in multiple cell line models with hyper-
activated mTORC1 signalling and elevated basal levels of ER stress. Unlike previous studies 
in cancer cell lines, we were able to test the hypothesis that loss of Tsc2 and consequent 
mTORC1 activation specifically sensitises cells to drug-induced ER stress and cell death. 
Importantly, we directly compared the effectiveness of nelfinavir and chloroquine in Tsc2-/- 
cell lines with matched controls expressing wild-type Tsc2 before validating our findings in a 
human non-small cell lung cancer cell line known to have abberant mTORC1 signaling due to 
an oncogenic KRAS mutation. We found chloroquine promotes nelfinavir-induced ER stress 
and cell death in mTORC1-hyperactive cells in an autophagy-independent manner. Our data 
suggests a novel therapeutic approach for killing tumour cells which have aberrant levels of 
mTORC1 activity and higher basal levels of ER stress.  
2. Materials and Methods 
2.1. Cell culture and reagents 
Tsc2+/+ p53-/- and Tsc2-/- p53-/- mouse embryonic fibroblasts (MEFs) were kindly provided 
by David J. Kwiatkowski (Harvard University, Boston, USA). Tsc2-/- ETL3 (Eker rat 
leiomyoma-derived cells) and control ELT3-Tsc2 cells in which Tsc2 is re-expressed were 
kindly provided by Cheryl Walker (M.D. Anderson Cancer Center, Houston, USA). Human 
embryonic kidney 293 (HEK293) cells and human lung carcinoma (NCI-H460) cells were 
purchased from ATCC. All cell lines were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 10 % (v/v) foetal bovine serum (FBS), 100 U/ml penicillin and 
100 µ/ml streptomycin (Life Technologies Ltd., Paisley, UK) in a humidified incubator at 37 
°C, 5 % (v/v) CO2. Nelfinavir mesylate hydrate, chloroquine di-phosphate salt, mefloquine 
hydrochloride, bafilomycin-A1, 3-methyladenine (3-MA) and thapsigargin were purchased 
from Sigma-Aldrich Company Ltd. (Dorset, UK). Nelfinavir, mefloquine, bafilomycin-A1 and 
thapsigargin were dissolved in dimethyl sulfoxide (DMSO) at 30 mM, 50 mM, 2.5 mM and 10 
mM stock solutions, respectively. Chloroquine was dissolved in fresh culture medium to a 
100 mM stock and further diluted in culture medium to the required concentrations for use. 
3-MA was dissolved in dH2O to a concentration of 100 mM. Drug(s) or DMSO vehicle control 
was added to cell culture medium in a manner that kept the final DMSO vehicle 
concentration below 0.5 % (v/v). 
2.2. mRNA extraction and reverse transcription 
Cells were plated onto 6 cm2 plates and allowed to adhere overnight. Following the 
appropriate treatment, cells were first washed in phosphate buffered saline (PBS) then lysed 
using 1 ml RNAprotect Cell Reagent (Qiagen, West Sussex, United Kingdom). RNA was 
extracted using the RNeasy Plus mini kit (Qiagen). Cell lysates were homogenized using 
Qiashredders (Qiagen) during the RNA extraction procedure. The concentration and purity 
of RNA was determined by measuring the absorbance at 260 nm and 280 nm in a Nanodrop 
spectrophotometer (Thermo Scientific, Hemel Hempsted, UK). Total RNA from each sample 
(1 μg) was transcribed into cDNA using Quantitect reverse transcription kit (Qiagen) in a 
thermal cycler (Applied Biosystems, California, USA). RNA, gDNA wipeout buffer and RNase-
free water at a final volume of 14 μl were incubated at 42 °C for 2 min. Quantiscript Reverse 
Transcriptase (Qiagen), Quantiscript RT buffer (Qiagen) and primers were added to a final 
volume of 20 μl and samples incubated at 42 °C for 15 min followed by 95 °C for 3 min.  
2.3. Detection of endoplasmic reticulum stress  
Quantitative PCR (Q-PCR) reactions were conducted in 96 well plates (Thermo Fisher, 
Loughborough, UK) using 25 ng DNA per reaction, appropriate primer sets and SYBR Green 
PCR Master mix (Qiagen). Quantitect β-actin and C/EBP Homologous Protein (CHOP) primers 
were purchased from Qiagen. Q-PCR was performed using an Applied Biosystems 7500 real-
time cycler as follows: initial denaturation step (95 °C, 15 min); 40 cycles of denaturation (94 
°C, 15 sec); annealing step (55 °C, 30 sec); extension step (72 °C, 30 sec). The amplification 
products were quantified during the extension step in the 40th cycle. Relative quantification 
was performed using the comparative CT method (ddCT) with β-actin as reference gene and 
DMSO vehicle-treated Tsc2+/+ MEFs as the calibrator. Melting curve analysis was performed 
to verify their specificity of the RT-PCR products. XBP1 primers [Forward: 5’-AAA CAG AGT 
AGC AGC TCA GAC TGC-3’, Reverse: 5’-TCC TTC TGG GTA GAC CTC TGG GA-3’] were 
synthesised through MWG Operon-Eurofin (Ebersberg, Germany). PCR was performed using 
an Applied Biosystems GeneAmp 9700 PCR system as follows: initial denaturation step (98 
°C, 3 min); 31 cycles of denaturation (9 °C, 30 sec); annealing step (60 °C, 30 sec); extension 
step (72 °C, 1 min). XBP1 products were run on 3% (w/v) agarose gels, 1 x Tris-Acetate-EDTA 
pH 8.0) using GelRed nucleic acid stain (Cambridge Bioscience, Cambridge, UK). DNA 
samples were prepared for loading by the addition of 5 x loading buffer. PCR products of X-
box binding protein 1 (XBP1) were 480 bp, unspliced, and 454 bp, spliced. 
2.4. Antibodies and Western Blotting 
Antibodies towards ribosomal protein S6 (rpS6), phospho-rpS6 (Ser235/236), p70-S6 kinase 
1 (S6K1), phospho-S6K1 (Th389), Acetyl-CoA carboxylase (ACC), phospho-ACC (Ser79), AMP-
dependent protein kinase (AMPK), phospho-AMPK (Thr172), binding immunoglobulin 
protein (BiP), inositol-requiring and ER-to-nucleus signalling protein 1α (IRE1α), TSC2 and β-
actin were purchased from Cell Signaling Technology (Danvers, USA). LC3 antibody was 
purchased from Novus Ltd. (Cambridge, UK), while the antibody for Sequestesome 1 
(SQSTM1) was purchased from Progen Biotecknik (Heidelberg, Germany). Cells were washed 
in PBS and then lysed in radio immunoprecipitation assay (RIPA) buffer (Sigma-Aldrich) 
supplemented with Complete Mini protease inhibitor cocktail, PhosSTOP phosphatase 
inhibitor cocktail (Roche Diagnostics Ltd., Burgess Hill, UK) and 1 mM dithiothreitol (DTT) at 
4 °C. Following centrifugation at 13,000 rpm for 8 min at 4 °C, protein concentrations were 
optimised by Bradford assay (Sigma-Aldrich). Samples were diluted in x 4 NuPAGE loading 
sample buffer (Life Technologies) with 25 mM DTT and boiled at 70 °C for 10 min. Western 
blot was performed as previously described (Dunlop et al., 2011). β-actin was used to as a 
control for equal protein loading.  
2.5. Cell viability assay 
Cells were plated at 100 % confluency (5 x 103/well) in a 96-well plate. Drug or DMSO 
vehicle was added and the plates incubated at 37 °C for 48 h. Media was removed from the 
cells and the plates frozen at -80 °C. Following thawing, 200 µl CyQuant mix, prepared as 
described in the CyQUANT Cell Proliferation Assay (Life Technologies) manufacturer’s 
handbook, was added to each well. Fluorescence was measured using a FLUOstar OPTIMA 
fluorometer (BMG LABTECH, Buckinghamshire, UK) at 485 nm and 520 nm. To determine 
cell number, counted cells were co-analysed as a standard curve. Results are expressed 
relative to untreated Tsc2+/+ cells which are assigned a value of 100 %. 
2.6. DNA fragmentation ELISA 
DNA fragmentation was measured with the Cell Death Detection ELISA kit (Roche) according 
to the manufacturer’s protocol. This one-step colorimetric sandwich ELISA allows relative 
quantification of histone-complexed DNA fragments which are indicative of apoptosis. 5 x 
103 cells were plated in 96-well plates and incubated overnight. Drugs were added to the 
required concentration and cells were incubated for 48 h. The relative quantity of 
immobilized antibody-histone complex was determined photometrically with absorbance at 
405 nm using 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid as a peroxidase 
substrate. Results are expressed relative to untreated Tsc2+/+ cells which were assigned a 
value of 1. 
2.7. Late cell death assay 
For assessment of cell viability, treated cells were incubated with 3 µM DRAQ7 for 10 min at 
37 ˚C prior to flow cytometry using excitation at 488 nm and detection of fluorescence in log 
mode at wavelengths greater than 695 nm (far red). Flow cytometry was performed using a 
FACS Calibur flow cytometer (Becton Dickinson, Cowley, UK) and Cell Quest Pro software 
(Beckton Dickinson Immunocytometry Systems) was used for signal acquisition. To control 
for autofluorescence, unstained cells were also analysed. Correlated signals were collected 
for a minimum of 10,000 events.  
2.8. Statistical analysis 
Experiments were carried out at least 3 times. Where applicable, results are expressed as 
mean ± standard deviation (SD). Student’s t-test and ANOVA were used and significance 
reported at p ≤ 0.05. 
  
3. Results 
3.1. Nelfinavir induces ER stress in Tsc2-/- MEFs 
We initially assessed ER stress after 3 h treatment with 20 µM nelfinavir in Tsc2+/+ and 
Tsc2-/- MEF cell lines by measurement of CHOP mRNA (Figure 1A). In DMSO vehicle 
treatment, Tsc2-/- MEFs had over 3-fold increase in relative expression of CHOP mRNA 
compared to wild-type MEFs, which indicates an elevated basal level of ER stress in the 
absence of Tsc2. Although nelfinavir increased CHOP mRNA levels in both cell lines, relative 
expression was more pronounced in the Tsc2-/- MEFs (4 times more when compared to 
Tsc2+/+, Figure 1A). These data suggest that the Tsc2-/- MEFs are more sensitive to 
nelfinavir-induced ER stress than the wild-type cells, which is concurrent with previous 
findings (Ozcan et al., 2008). Thapsigargin, a potent inducer of ER stress, served as a positive 
control which enhanced CHOP mRNA expression in both MEF cell lines. To confirm ER stress-
induction, we also analysed XBP1 mRNA splicing as a reliable readout of nelfinavir-induced 
ER stress (Brüning, 2011). We observed a higher basal level of XBP1 mRNA splicing in Tsc2-/- 
cells (Figure 1B) and nelfinavir also selectively induced ER stress in the Tsc2-/- MEFs as 
observed by increased splicing (compare lane 5 versus lane 2). In both MEF cell lines, 
thapsigargin led to complete XBP1 mRNA splicing. We next measured protein expression of 
BiP and IRE1α which are considered common markers of ER stress (Figure 1C). Both BiP and 
IRE1α protein levels were elevated in the Tsc2-/- MEFs, which further confirms that cells 
lacking Tsc2 have a higher basal level of ER stress. However, 3 h treatment of either 
nelfinavir or thapsigargin failed to further enhance BiP or IRE1α protein in the Tsc2-/- MEFs, 
presumably as ER stress levels were already basally high (Siroky et al., 2012, Kang et al., 
2011, Ozcan et al., 2008). 
3.2. Nelfinavir inhibits mTORC1 signal transduction and induces autophagy 
We next analysed mTORC1 signal transduction in the Tsc2+/+ and Tsc2-/- MEFs by 
examining rpS6 phosphorylation (Figure 2A). In the Tsc2+/+ MEFs, we observed complete 
inhibition of rpS6 phosphorylation after nelfinavir treatment but inhibition of mTORC1 
signalling was incomplete in the Tsc2-/- MEFs, which reveals nelfinavir requires Tsc2 for full 
repression of mTORC1 signalling. Cell quantification assays revealed that nelfinavir reduced 
the number of Tsc2-/- cells by 16%, whereas Tsc2+/+ MEFs were unaffected (Figure 2B). 
Furthermore, there was a 3-fold increase in DNA fragmentation of Tsc2-/- MEFs compared 
to Tsc2+/+ after 48 h exposure to nelfinavir (Figure 2C), which indicates that loss of Tsc2 
sensitises cells to nelfinavir-induced cytotoxicity. Given that autophagy is modulated by 
both mTORC1 and ER stress, we next examined markers of autophagy after treatment with 
nelfinavir. Untreated Tsc2-/- MEFs had a lower level of autophagy when compared to the 
Tsc2+/+ MEFs, as observed by increased protein accumulation of SQSTM1 (Figure 2D). Both 
nelfinavir and thapsigargin increased autophagy as observed by decreased SQSTM1 protein. 
Increased LC3 lipidation to the lower resolving LC3-II isoform suggest either increased 
autophagy or a block in late stage autophagy (or both). Furthermore, we observed marked 
activation of AMPK upon treatment with nelfinavir, via increased phosphorylation of AMPK 
and its substrate, ACC (Figure 2D). 
To validate some of our initial findings, we examined the effects of nelfinavir on mTORC1 
signalling and autophagy after acute insulin stimulation in HEK293 cells (Figure 2E). The high 
level of insulin-induced rpS6 phosphorylation was completely abolished upon treatment 
with nelfinavir. SQSTM1 protein levels were also markedly reduced with nelfinavir, which 
again suggests enhanced autophagy fluxing. Similar to the effects we observed in the MEF 
cell lines, both nelfinavir and thapsigargin strongly induced LC3-II accumulation. 
3.3. Chloroquine enhances nelfinavir-induced cell death in Tsc2-/- cells 
Given that autophagy is a well-established survival mechanism employed by cells to 
alleviate ER stress, we wanted to determine whether inhibition of autophagy would 
enhance the potency of nelfinavir to selectively kill Tsc2-/- cells. To do this we used 
chloroquine which blocks autophagy during the final stages. Analysis of S6K1 
phosphorylation revealed that chloroquine alone did not affect mTORC1 signal transduction 
but combination with nelfinavir was particularly effective at reducing S6K1 phosphorylation 
in Tsc2+/+ MEFs and modestly in Tsc2-/- MEFs (Figure 3A). Chloroquine treatment blocked 
autophagy, more effectively in the presence of nelfinavir, as observed by an accumulation of 
LC3-II (Figure 3A). In the Tsc2-/- MEFs, a combination of nelfinavir and chloroquine was 
much more effective at induction of CHOP mRNA levels (by 27 %, Figure 3B) and XBP1 
splicing (Figure 3C), than either agent alone. 
We next measured cell death by flow cytometry after staining with DRAQ7. DRAQ7 is a 
membrane impermeable far-red fluorescence DNA-binding stain that is used to measure cell 
death as a consequence of increased membrane permeability. Events were gated to exclude 
fragmented cells and debris before gating viable and non-viable populations according to 
DRAQ7 staining. Combined 24 h treatment with nelfinavir and chloroquine selectively killed 
Tsc2-/- MEFs by an average of 43% compared to 6% cell death in Tsc2+/+ MEFs (Figure 4A 
and 4B). Using DNA fragmentation ELISA we found 48 h combined nelfinavir and 
chloroquine led to over 5-fold increase in relative DNA fragmentation in Tsc2-/- MEFs when 
compared to nelfinavir treatment alone (Figure 4C).  
3.4 Enhancement of nelfinavir-induced cell death is not due to autophagy inhibition by 
chloroquine 
To confirm that enhancement of nelfinavir-induced cell death was due to autophagy 
inhibition by chloroquine, Tsc2+/+ and Tsc2-/- MEFs were treated with two other known 
inhibitors of autophagy, bafilmycin-A1 and 3-methyladenine (3-MA), in combination with 
nelfinavir. Analysis by western blot following 3 h of treatment confirmed bafilomycin-A1 
inhibited autophagy comparible to chloroquine, as shown by increased levels of SQSTM1 
and LC3-II (Figure 5A). 3-MA is known to have differing effects on autophagy depending on 
nutrient status (Wu et al., 2010). Therefore, the lack of observed autophagy inhibition by 3-
MA was unsurprising. Interestingly, 24 h treatment with combined nelfinavir and 
bafilomycin-A1 or nelfinavir and 3-MA failed to induce Tsc2-/- cell death to a similar extent 
as combined nelfinavir and chloroquine (on average 3% and 7% vs 25%, respectively, Figure 
5B-C). To determine whether cell death was exclusive to chloroquine, We analysed the 
chloroquine analogue, mefloquine, and found it to be highly effective at killing Tsc2-/- MEFs 
in combination with nelfinavir (on average 63%). Further supporting autophagy inhibition is 
not the underlying mechanism by how these chloroquine compounds sensitise Tsc2-/- cells 
to nelfinavir, mefloquine did not repress autophagy (as observed by low levels of SQSTM1 
and no accumulation of lipidated LC3-II, Figure 5A). Collectively, our data implies that 
chloroquine sensitises nelfinavir-induced cell death via a mechanism that is not autophagy 
inhibition. To explore other possible mechanisms of drug action, we combined nelfinavir 
and chloroquine treatment with bafilomycin-A1, which blocks the v-ATPase and prevents 
entrapment of chloroquine to lysosomes and late endosomes. We observed that 
bafilomycin-A1 robustly rescued cell death by nelfinavir and chloroquine in the Tsc2-/- MEFs 
(Figure 5B). This indicates that entrapment of chloroquine to acidified lysosomes and late 
endosomal compartments is required for chloroquine-mediated enhancement of nelfinavir-
induced cell death. 
To confirm the cytotoxic effects of combined nelfinavir and chloroquine, we utilised another 
well-established Tsc2-/- cell line model, the ELT3 rat smooth muscle cell line (Eker et al., 
1983). Similar to the MEFs, 3 h combined treatment with nelfinavir and chloroquine reduced 
phosphorylation of S6K1, lowered SQSTM1 protein and enhanced levels of LC3-II in ELT3-V3 
(Tsc2-/-) cells (Figure 6A). Cell viability was significantly reduced in ELT3-V3 cells compared 
to ELT-T3 cells following 48 h of combined nelfinavir and chloroquine treatment (Figure 6B). 
Cell death assays following 48 h of treatment showed selective cell death in ELT3-V3 cells by 
an average of 34% compared to 9% in ELT3-T3 (Tsc2+/+) cells (Figure 5C, 5D). Similarly to 
the Tsc2-/- MEFs, the ELT3-V3 cells were almost 5-fold more sensitive to 48 h combined 
treatment of nelfinavir and chloroquine when compared to ELT3-T3 cells, as determined by 
DNA fragmentation (Figure 6E).  
3.5 Combined nelfinavir and chloroquine effectively kills cancer cells with over-active 
mTORC1 
To validate our previous findings in a cancer cell line with over-active mTORC1, NCI-H460 
human lung carcinoma cells were treated with nelfinavir and chloroquine. As a control, 
rapamycin was used to inhibit mTORC1 signaling in these cells. Similar to the MEF and ELT3 
cell lines, 3 h combined nelfinavir and chloroquine treatment reduced both phosphorylated 
rpS6 and S6K1 signaling and increased levels of LC3-II (Figure 7A). As expected, rapamycin 
completely inhibited both rpS6 and S6K1 phosphorylation. 48 h combination treatment with 
nelfinavir and chloroquine effectively killed NCI-H460 cells by an average of 49% which 
appeared to be partially rescued by the addition of rapamycin to an average of 26% 
although this trend was not significant (P=0.127, Figure 7B, 7C). This suggests mTORC1 
activity contributes to induction of cell death following treatment with nelfinavir and 
chloroquine.  
4. Discussion 
In this study we show that combination of nelfinavir and chloroquine is selectively cytotoxic 
to Tsc2-/- cells. Importantly, we were able to directly compare the potency of this drug 
combination in Tsc2-/- cell lines with matched controls expressing wild-type Tsc2. Tsc2-/- 
cells exhibit constitutive mTORC1 activation, high levels of basal ER stress and impaired 
autophagy. We show a combination of nelfinavir and chloroquine potentiated ER stress and 
affected autophagy in Tsc2-/- cells. 
Unfolded proteins in the ER are not exclusively removed via the autophagy pathway; protein 
aggregates are also removed via the proteasome (Rubinsztein, 2006). Nelfinavir has 
previously been shown to inhibit the proteasome (Bono et al., 2012, Gupta et al., 2007), 
suggesting inhibition of the proteasome allows accumulation of unfolded protein aggregates 
in the ER, leading to enhanced ER stress and consequent autophagy induction. Despite 
observing changes to the autophagy flux upon nelfinavir and chloroquine or nelfinavir and 
bafilomycin-A1 treatment, induction of cell death was exclusive to the use of nelfinavir with 
chloroquine or its analogue, mefloquine. In contrast to chloroquine, mefloquine did not 
inhibit autophagy in the MEF cell lines (Figure 5A). Supporting our findings, Shin et al., 2012 
showed mefloquine to induce autophagy, and combined autophagy repression with 3-MA 
aggravated mefloquine-mediated cytotoxicity. Our data indicates an autophagy-
independent role for chloroquine is the underlying mechanism of enhanced sensitivity to 
nelfinavir-induced cell death: entrapment of chloroquine to acidified lysosomal/endosomal 
compartments was necessary for cytotoxicity, as we observed bafilomycin-A1 inhibition of 
v-ATPase (Klionsky et al., 2008) prevented nelfinavir and chloroquine-induced cell death. 
Our results are in accordance with previous data showing nutrient deprivation combined 
with chloroquine treatment effectively killed glioma, melanoma and fibrosarcoma cells 
which was not replicated with bafilomycin-A1, and that addition of bafilomycin-A1 was able 
to rescue the effects of chloroquine (Harhaji-Trajkovic et al., 2012). 
Cells lacking Tsc2 have a truncated ER stress response (Kang et al., 2011), implying that TSC2 
is required for a normal response to ER stress. There are several signalling mechanisms 
which converge upon mTORC1 during a normal ER stress response: GADD34 recruits protein 
phosphatase 1 (PP1) which activates TSC2 through dephosphorylation and subsequent 
inhibition of Rheb/mTORC1 (Uddin et al., 2011, Watanabe et al., 2007, Kojima et al., 2003). 
As we observed increased AMPK activation (Figure 2D), nelfinavir likely inhibits mTORC1 
through AMPK-mediated TSC2 activation. This method of mTORC1 inhibition through AMPK 
has been previously established in Tsc2-/- cells (Gwinn et al., 2008). Interestingly, recent 
research by Brüning et al., (2013) linked AMPK activation to ER stress through the sestrin 2 
(SESN2) protein. Furthermore, their research indicated that nelfinavir-mediated ER stress 
results in accumulation of Activating Transcription Factor 4 (ATF4), a known regulator of 
CHOP and SESN2 (Brüning et al., 2013). Nelfinavir also inhibits Akt (Gupta et al., 2005, 
Plastaras et al., 2008), which could activate TSC2 to further repress mTORC1 signalling (Tee 
et al., 2003). These various ER stress and nelfinavir TSC2-dependent signalling mechanisms 
may explain why rpS6 and S6K1 phosphorylation levels were markedly reduced in Tsc2+/+ 
MEFs, but only partially reduced in Tsc2-/- MEFs following nelfinavir treatment (Figure 2A 
and 3A). Therefore, nelfinavir may inhibit mTORC1 signal transduction through multiple 
mechanisms that require TSC2, i.e., via GADD34/PP1/TSC2, Akt/TSC2, and/or 
SESN2/AMPK/TSC2, all of which would be compromised in Tsc2-/- cells. We are currently 
investigating the drug actions of nelfinavir and chloroquine to induce cell death, and 
propose a mechanism in Figure 8.  
TSC2 appears vital for the survival of nelfinavir and chloroquine-treated cells. The enhanced 
sensitivity of Tsc2-/- cell lines to cell death could be due in part to the inability of nelfinavir 
to ablate mTORC1 signalling in these cells. One important feature of the ER stress response 
pathway is to block mTORC1 signalling for two main purposes: firstly, mTORC1 inhibition 
reduces the rate of protein synthesis, lessening the burden on the ER, and secondly, 
mTORC1 inhibition is required for a robust autophagy response, allowing efficient removal 
of unfolded protein aggregates in the ER. Therefore, activation of TSC2 and inhibition of 
mTORC1 appears to be critically important for cell survival during acute or prolonged ER 
stress. Frequent constitutive activation of mTORC1 signalling in cancer suggests that our 
observations may have wider relevance. In line with our work, nelfinavir effectively induced 
cell death when combined with chloroquine or mefloquine in breast cancer models (Thomas 
et al., 2012), medullary thyroid cancer cell lines (Kushchayeva et al., 2014), and a model of 
chronic lymphocytic leukaemia (Mahoney et al., 2013). Chloroquine in combination with 
rapamycin was also effective in Tsc2-/- MEFs (Parkhitko et al., 2011,).  
In conclusion, our data shows that mTORC1-hyperactive cells are sensitive to nelfinavir-
induced cell death, which is further enhanced by chloroquine through an autophagy-
independent mechanism involving its protonation and entrapment within lysosomes which 
is prevented by addition of bafilomycin-A1. In addition to therapeutic potential in the 
context of TSC and LAM, dual treatment with nelfinavir and chloroquine promises to be 
minimally toxic and efficacious in a range of tumour types featuring hyper-active mTORC1.  
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Figure Legends 
Figure 1 – Nelfinavir-induced ER stress is more pronounced in Tsc2-/- MEFs. Tsc2-/- and 
Tsc2+/+ MEFs were treated with either DMSO vehicle alone, 20 µM nelfinavir (NFV), or 1 µM 
thapsigargin (TPG) for 3 h. Cells were then appropriately harvested to analyse A) CHOP 
mRNA, which was standardised against -actin mRNA (n = 3, * p < 0.05), B) PCR products for 
XBP1 mRNA were resolved on agarose gels (unspliced = 480 bp upper band, spliced = 454 bp 
lower band). -actin is shown as a control. C) Protein extracts were analysed for BiP, IRE1 
and -actin levels. n=3, * p=<0.05. 
Figure 2 – Nelfinavir inhibits mTORC1, induces autophagy and selectively kills Tsc2-/- 
MEFs. Tsc2-/- and Tsc2+/+ MEFs were treated with either DMSO vehicle alone, 20 µM 
nelfinavir (NFV), or 1 µM thapsigargin (TPG) for 3 h. A) Total and phosphorylated ‘(P)-rpS6’, 
TSC2 and -actin were determined by western blot analysis from total protein lysates. 48 h 
DMSO and 20 µM nelfinavir-treated Tsc2-/- and Tsc2+/+ MEFs were subjected to B) cell 
viability and C) cell death assays. D) Samples (prepared as for A) were subjected to western 
blot analysis to determine total and phosphorylated ‘(P)-AMPK’, total and phosphorylated 
‘(P)-ACC’, and LC3 (‘LC3-I’ and ‘LC3-II’). E) HEK293 cells were pre-treated with either 20 µM 
nelfinavir or 1 µM thapsigargin as indicated for 30 min prior to 100 nM insulin stimulation 
for 30 min. Total and phosphorylated ‘(P)-rpS6’, LC3 ( ‘LC3-I’ and ‘LC3-II’) and -actin were 
then determined by western blot analysis from prepared cell lysates. n=3, * p=<0.05. 
Figure 3 – Chloroquine further sensitises Tsc2-/- MEFs to nelfinavir-induced ER stress. 
Tsc2-/- and Tsc2+/+ MEFs were treated with DMSO vehicle alone, 20 µM nelfinavir (NFV), 
and/or chloroquine (CQ, 10 µM and 20 µM) as indicated. A) Following 3 h drug treatment, 
protein lysates were subjected to western blot analysis to determine levels of total and 
phosphorylated ‘(P)-rpS6’, total and phosphorylated ‘(P)-S6K1, LC3-II, TSC2 and -actin. B) 
CHOP mRNA was analysed and standardised against -actin (n = 3, * p < 0.05). C) PCR 
products for XBP1 mRNA were resolved on agarose gels (unspliced = 480 bp upper band, 
spliced = 454 bp lower band). -actin mRNA is shown as a control. n=3, * p=<0.05. 
Figure 4 – Combined treatment of nelfinavir and chloroquine selectively kills Tsc2-/- MEFs. 
Tsc2-/- and Tsc2+/+ MEFs were treated with either DMSO vehicle alone, 20 µM nelfinavir 
(NFV), 20 µM chloroquine (CQ), or both NFV and CQ over 24 h and subjected to cell death 
assays. A) For quantification of cell death, Tsc2+/+ and Tsc2-/- MEFs were subjected to flow 
cytometry analysis following DRAQ7 staining. DRAQ7 exclusion (below line) represents the 
viable cell population, whilst positive DRAQ7 staining (above line) indicates cell death. The 
number of DRAQ7-stained cells are graphed in B. C) Relative DNA fragmentation as 
determined by cell death ELISA. n=3, * p=<0.05. 
Figure 5 – Combination treatments of nelfinavir and bafilomycin-A1 or nelfinavir and 3-
methyladenine fail to kill Tsc2-/- MEFs. Tsc2-/- and Tsc2+/+ MEFs were treated with either 
DMSO vehicle alone, 2.5 µM baflilomycin-A1 (BAF), 10 mM 3-methyladenine (3-MA), 10 µM 
mefloquine (MQ) or combined nelfinavir (NFV) BAF/3-MA/MQ. A) Following 3 h drug 
treatment, protein lysates were subjected to western blot analysis to determine levels of 
LC3-II, SQSTM1 and -actin. B) For quantification of cell death following 48 h of treatment, 
Tsc2-/- and Tsc2+/+ MEFs were subjected to flow cytometry analysis following DRAQ7 
staining. DRAQ7 exclusion (below line) represents the viable cell population, whilst positive 
DRAQ7 staining (above line) indicates cell death. The number of DRAQ7-stained cells are 
graphed in C. n=3, * p=<0.05. 
Figure 6 – Combined treatment of nelfinavir and chloroquine selectively kills Tsc2-/- ELT3 
cells. Tsc2-/- and Tsc2+/+ ELT3 cells were treated with either DMSO vehicle alone, 20 µM 
nelfinavir (NFV), 20 µM chloroquine (CQ), or both NFV and CQ and subjected to western blot 
and death assays. A) Following 3 h drug treatment, protein lysates were subjected to 
western blot analysis to determine levels of total and phosphorylated ‘(P)-rpS6’, total and 
phosphorylated ‘(P)-S6K1, LC3-II, SQSTM1, TSC2 and -actin. B) Quantification of cell 
viability. C) For quantification of cell death following 48 h of treatment, Tsc2+/+ and Tsc2-/- 
ELT3 cells were subjected to flow cytometry analysis following DRAQ7 staining. DRAQ7 
exclusion (below line) represents the viable cell population, whilst positive DRAQ7 staining 
(above line) indicates cell death. The number of DRAQ7-stained cells are graphed in D. E) 
Relative DNA fragmentation as determined by cell death ELISA. n=3, * p=<0.05. 
Figure 7 – Combined treatment of nelfinavir and chloroquine kills NCI-H460 lung cancer 
cells. NCI-H460 cells were treated with either DMSO vehicle alone, 20 µM nelfinavir (NFV), 
20 µM chloroquine (CQ), or both NFV and CQ and subjected to western blot and death 
assays. 100 nm rapamycin was used to inhibit mTORC1 signaling. A) Following 3 h drug 
treatment, protein lysates were subjected to western blot analysis to determine levels of 
total and phosphorylated rpS6, total and phosphorylated S6K1, LC3-II, SQSTM1 and -actin. 
B) For quantification of cell death following 48 h of treatment, NCI-H460 cells were 
subjected to flow cytometry analysis following DRAQ7 staining. DRAQ7 exclusion (below 
line) represents the viable cell population, whilst positive DRAQ7 staining (above line) 
indicates cell death. The number of DRAQ7-stained cells are graphed in C. n=3. 
Figure 8 – Chloroquine augments nelfinavir-induced ER stress and cell death 
independently of autophagy. In normal cells, nelfinavir-induced ER stress inhibits mTORC1 
de novo protein synthesis through two survival pathways, GADD34 and AMPK, which both 
directly activate the TSC protein complex. In TSC-deficient cells or when mTORC1 is 
oncogenically activated, ER stress is less efficient at repressing mTORC1 signalling, further 
enhancing ER stress through continual protein production and autophagy inhibition. 
Prolonged, elevated ER stress produces a lethal outcome in cells unable to alleviate mTORC1 
activation. Entrapment of chloroquine to lysosomes is required for enhancement of 
nelfinavir-induced cell death. 
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